- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
ADAC warns of lower Q2 results
Nuclear medicine developer ADAC Laboratories issued a warning to the financial markets on April 21, stating that the Milpitas, CA, company expects to post lower than anticipated profits and revenues for the second quarter (end-April). ADAC believes that
Nuclear medicine developer ADAC Laboratories issued a warning to the financial markets on April 21, stating that the Milpitas, CA, company expects to post lower than anticipated profits and revenues for the second quarter (end-April). ADAC believes that revenues could be 2% to 8% lower than the $94.3 million it reported for the first quarter, while earnings per share will decline significantly. The news prompted Wall Street to pummel ADAC shares: The stock was trading at around $6.25 on April 22, down 50% from the day before.
ADAC said that a weakening of demand in nuclear medicine was one of the factors leading to the lower results. Orders for the second quarter declined 12% compared with the first quarter. ADAC also said that it has experienced delays in recognizing revenue under the new revenue recognition policy adopted by the company.
ADAC may also incur one-time charges in the second quarter, for both international accounts receivable and for shareholder class-action litigation related to its revenue restatement this year. Additionally, the company may take a charge in connection with the restructuring of its distribution and manufacturing operations.
It is unclear whether ADACs problems are limited to the company, or are a sign of a broader slowdown in the nuclear medicine market that could affect other firms. ADAC expects to post complete second-quarter results by the second half of May.
© 1999 Miller Freeman, Inc.All rights reserved.
Study Reveals Benefits of Photon-Counting CT for Assessing Acute Pulmonary Embolism
April 23rd 2024In comparison to energy-integrating detector CT for the workup of suspected acute pulmonary embolism, the use of photon-counting detector CT reduced radiation dosing by 48 percent, according to newly published research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
AI Adjudication Bolsters Chest CT Assessment of Lung Adenocarcinoma
April 11th 2024The inclusion of simulated adjudication for resolving discordant nodule classifications in a deep learning model for assessing lung adenocarcinoma on chest CT resulted in a 12 percent increase in sensitivity rate.
